- Iobenguane I 123 Injection Studied for Its Ability to Identify Risk in Patients with Symptomatic Heart Failure (HF)
PRINCETON, NJ, May 17, 2010 --The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) trial, the results of which were published in the May 18th, 2010 issue of the Journal of the American College of Cardiology, is a prospective study evaluating cardiac sympathetic nerve imaging using Iobenguane I 123 Injection (AdreView™) for identifying symptomatic heart failure patients most likely t